Mesoblast Sees Chance For Faster Phase III Heart Failure Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The Australian stem cell company said a Phase III trial being run by partner Teva and testing MPC-150-IM in chronic heart failure could finish earlier than expected because of an interim superiority analysis.